Centaurus Financial Inc. acquired a new stake in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 4,215 shares of the exchange traded fund’s stock, valued at approximately $416,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Tidemark LLC raised its position in shares of SPDR S&P Biotech ETF by 101.5% in the third quarter. Tidemark LLC now owns 395 shares of the exchange traded fund’s stock valued at $39,000 after buying an additional 199 shares during the last quarter. ORG Partners LLC purchased a new stake in SPDR S&P Biotech ETF during the 2nd quarter valued at about $40,000. Quintet Private Bank Europe S.A. acquired a new stake in SPDR S&P Biotech ETF in the 3rd quarter valued at about $40,000. ORG Wealth Partners LLC acquired a new stake in SPDR S&P Biotech ETF in the 3rd quarter valued at about $44,000. Finally, Howe & Rusling Inc. purchased a new position in SPDR S&P Biotech ETF in the 3rd quarter worth approximately $49,000.
SPDR S&P Biotech ETF Price Performance
XBI stock opened at $98.80 on Wednesday. SPDR S&P Biotech ETF has a 1 year low of $71.99 and a 1 year high of $105.47. The firm has a market capitalization of $7.53 billion, a PE ratio of 11.47 and a beta of 1.11. The business has a 50 day simple moving average of $98.37 and a 200-day simple moving average of $96.38.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Further Reading
- Five stocks we like better than SPDR S&P Biotech ETF
- What is a Bond Market Holiday? How to Invest and Trade
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- The How and Why of Investing in Gold Stocks
- Why Amazon Shares May Never Trade Below $200 Again
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.